Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
Active, not recruiting · NCT04305145 · Registry updated 2026-06-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis | Chemically-Induced Disorders, Digestive System Diseases, Drug Toxicity, Drug-Related Side Effects and Adverse Reactions, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, intestinal disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 2 | 2026-06-16 | NCT04305145 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| Massachusetts General Hospital | 758 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Massachusetts General Hospital Cancer Center | Boston | United States | 178 |